Form 4: Director's Options Cashed Out in Astria Therapeutics Merger

Astria Therapeutics director Joanne Beck's stock options were canceled for cash or no consideration following the company's merger with BioCryst Pharmaceuticals' subsidiary.

Summary

• Joanne T. Beck, a director of Astria Therapeutics, Inc., reported changes in beneficial ownership due to a corporate merger.
• On January 23, 2026, Astria Therapeutics, Inc. merged with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc., resulting in Astria becoming a wholly-owned subsidiary of BioCryst.
• In-the-money stock options (those with an exercise price less than $13.00) held by Ms. Beck were fully vested, exercisable, and subsequently canceled in exchange for a cash payment.
• The cash payment for in-the-money options was calculated as the product of the total number of shares subject to the option and the excess of $13.00 (the merger price) over the option's exercise price.
• Out-of-the-money stock options (those with an exercise price equal to or greater than $13.00) were canceled for no consideration and are not reported in this filing.
• Ms. Beck's reported in-the-money options included 16,666 options at an exercise price of $12.24, 8,333 options at $3.00, 14,100 options at $11.35, 14,100 options at $9.18, and 26,550 options at $5.79.
• The 16,666 options at $12.24 were adjusted to reflect a 1-for-6 reverse stock split effected by Astria Therapeutics on August 19, 2021.
• Following these transactions, Ms. Beck beneficially owns 0 derivative securities of Astria Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for in-the-money option holders who received cash. However, it is negative for out-of-the-money option holders who received no consideration. The company's cessation as an independent public entity represents a definitive outcome, which can be viewed as neutral for the company itself but a final exit for its public shareholders.

Positives

• Holders of in-the-money options, including the reporting person, received cash payouts for their options, providing a liquidity event at the merger price of $13.00 per share.

Negatives

• Out-of-the-money options were canceled for no consideration, resulting in a complete loss of value for those specific options.
• Astria Therapeutics, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.

Risks

• Option holders whose exercise price was equal to or greater than $13.00 received no value for their options due to the cancellation without consideration.
• The merger eliminates Astria Therapeutics as a standalone public entity, removing its independent growth potential and public market presence for investors.

Future Outlook

This filing primarily reports a past corporate action and its impact on insider stock options. It does not provide forward-looking statements or guidance for Astria Therapeutics as an independent entity, as it is now a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc. Any future outlook for the acquired assets would be integrated into BioCryst Pharmaceuticals' reporting.

Industry Context

This filing reflects a common consolidation event within the biotechnology or pharmaceutical industry, where a smaller company like Astria Therapeutics is acquired by a larger entity such as BioCryst Pharmaceuticals. Such mergers and acquisitions are frequently driven by strategic objectives, including the acquisition of promising drug pipelines, market expansion, or the realization of operational synergies. The treatment of stock options in this manner is standard practice in M&A transactions.

Comparison to Industry Standards

• Mergers and acquisitions are a standard part of the lifecycle for many biotech companies, often providing an exit for investors and a strategic asset for the acquirer.
• The treatment of stock options in a merger, with in-the-money options cashed out and out-of-the-money options canceled, is a common practice in M&A transactions, aligning with typical industry standards for corporate control changes.
• The 1-for-6 reverse stock split by Astria Therapeutics in 2021, prior to the merger, suggests the company may have been addressing share price concerns or seeking to maintain listing requirements, a common move for companies in the biotech sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Astria Therapeutics: Received cash consideration for their shares as part of the merger (implied by the option treatment and the company becoming a wholly-owned subsidiary).
• Option Holders of Astria Therapeutics: Those with in-the-money options received cash payouts, while those with out-of-the-money options received no value.
• Employees of Astria Therapeutics: Likely integrated into BioCryst Pharmaceuticals' operations or subject to restructuring, though specific details are not provided in this filing.
• BioCryst Pharmaceuticals: Successfully acquired Astria Therapeutics, potentially expanding its pipeline, market presence, or strategic assets.

Next Steps

• BioCryst Pharmaceuticals, Inc. will proceed with the integration of Astria Therapeutics, Inc. into its operations.
• Former Astria Therapeutics shareholders and option holders would have received their merger consideration as per the agreement.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Stock Options, Form 4, Insider Transaction, Corporate Action, Acquisition, Director Compensation